Clinical Evaluation of SRT-017 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

计划入组 18 人 · 首次发布于 2026 年 9 月 1 日

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

计划入组 670 人 · 首次发布于 2026 年 5 月 28 日

68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

计划入组 49 人 · 首次发布于 2025 年 12 月 30 日

Lutetium Lu-177 vipivotide tetraxetan(Pluvicto)

C₄₉H₆₈LuN₉O₁₆

p300 degraders (oral, cancer/metastatic castration-resistant prostate cancer)

ACK1 inhibitors (castration-resistant prostate cancer)

Arvinas

United States

Cardiff Oncology

United States

Acurx Pharmaceuticals

United States

Quebec Expands Public Reimbursement of Pluvicto Radioligand Therapy for Advanced Prostate Cancer

FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

PSMA-Targeted Therapies Transform Prostate Cancer Treatment Landscape